Merck 3Q Revenues: $17.3 billion (+4%) 3Q Earnings: $5.8 billion (+83%) YTD Revenues: $48.6 billion (flat) YTD Earnings: $15.3 (+14%) Comments: KEYTRUDA sales were up 10% to $8.1 billion driven by continued global demand and uptake in earlier-stage indications. GARDASIL/GARDASIL 9 sales declined 24% to $1.7 billion primarily due to lower demand in China, lower demand in Japan, partially offset by higher sales in the U.S. due to higher pricing. PROQUAD, M-M-R II and VARIVAX sale...